1.66
-0.085(-4.89%)
Currency In USD
| Previous Close | 1.74 |
| Open | 1.74 |
| Day High | 1.78 |
| Day Low | 1.64 |
| 52-Week High | 4.4 |
| 52-Week Low | 1.23 |
| Volume | 423,049 |
| Average Volume | 680,373 |
| Market Cap | 62.14M |
| PE | -0.69 |
| EPS | -2.39 |
| Moving Average 50 Days | 2.29 |
| Moving Average 200 Days | 1.93 |
| Change | -0.09 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $160.52 as of December 13, 2025 at a share price of $1.655. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $160.52 as of December 13, 2025 at a share price of $1.655.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced
Metagenomi to Present at Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
GlobeNewswire Inc.
Nov 11, 2025 9:01 PM GMT
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11,